Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 21, 2024

Ibrutinib Plus Immunochemotherapy With or Without ASCT vs Immunochemotherapy and ASCT for Previously Untreated Mantle Cell Lymphoma

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Lancet 2024 May 02;[EPub Ahead of Print], M Dreyling, J Doorduijn, E Giné, M Jerkeman, J Walewski, M Hutchings, U Mey, J Riise, M Trneny, V Vergote, O Shpilberg, M Gomes da Silva, S Leppä, L Jiang, S Stilgenbauer, A Kerkhoff, RD Jachimowicz, M Celli, G Hess, L Arcaini, C Visco, T van Meerten, S Wirths, PL Zinzani, U Novak, P Herhaus, F Benedetti, K Sonnevi, C Hanoun, M Hänel, J Dierlamm, C Pott, W Klapper, D Gözel, C Schmidt, M Unterhalt, M Ladetto, E Hoster

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading